Cargando...
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: al...
Guardado en:
| Publicado en: | Expert Rev Anticancer Ther |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2009
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5176249/ https://ncbi.nlm.nih.gov/pubmed/19445582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.09.14 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|